Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.41 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.41 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.41 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | FNTA | P49354 | 1/20 | 0.39 |
| ▸ | FNTB | P49356 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11814670 | 0.90 | HTT (0.47) | HTTSRD5A2HRH3PTGS2CXCL8 | |
| SCHEMBL15641391 | 0.86 | PTGS1 (0.56) | SRD5A2PTGS2CXCL8AKR1B1PTGS1 | |
| SCHEMBL15641390 | 0.86 | PTGS1 (0.56) | SRD5A2PTGS2CXCL8AKR1B1PTGS1 | |
| SCHEMBL11822151 | 0.86 | HTT (0.43) | HTTSRD5A2HRH3PTGS2CXCL8 | |
| SCHEMBL11810218 | 0.85 | PTGS1 (0.41) | HTTPTGS2CXCL8AKR1B1PTGS1 | |
| SCHEMBL7678249 | 0.84 | PTGS2 (0.44) | HTTHRH3PTGS2CXCL8AKR1B1 | |
| SCHEMBL7682271 | 0.83 | SMN1; SMN2 (0.44) | HRH3PTGS2CXCL8PTGS1MAPK1 | |
| SCHEMBL11811925 | 0.83 | TSHR (0.45) | HTTSRD5A2HRH3PTGS2CXCL8 | |
| SCHEMBL7685006 | 0.82 | HTT (0.54) | HTTPTGS2PTGS1MAPK1HPGD | |
| SCHEMBL11091486 | 0.81 | PTGS1 (0.33) | PTGS2CXCL8AKR1B1PTGS1GLO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0948483-A1 | FARNESYL TRANSFERASE INHIBITORS | Aventis Pharma S.A. (FR) | 1999-10-13 | — | — | EP | claimed |
| WO-1998029390-A1 | FARNESYL TRANSFERASE INHIBITORS | RHONE-POULENC RORER S.A. (FR) | 1998-07-09 | — | — | WO | claimed |
| US-6455703-B2 | ADMINISTERING EFFECTIVE AMOUNT OF 1,3,6-TRIHYDRO-6-AZA-3-OXAPENTALEN-2-ONE DERIVATIVE TO THE PATIENT FOR INDUCING OR PROMOTING APOPTOSIS AND FOR ARRESTING UNCONTROLLED NEOPLASTIC CELL PROLIFERATION | CELL PATHWAYS, INC. | 2002-09-24 | — | — | US | disclosed |
| US-20010051651-A1 | 1,3,6,-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia | OSI PHARMACEUTICALS, INC. | 2001-12-13 | — | — | US | disclosed |
| US-6160003-A | 1,3,6-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia | CELL PATHWAYS, INC. (US) | 2000-12-12 | — | — | US | disclosed |
| US-5939417-A | 1,3,6-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia | CELL PATHWAYS INC (US) | 1999-08-17 | — | — | US | disclosed |
| US-5721347-A | Esters and amides of substituted pyrrole acetic acids | CELL PATHWAYS, INC. (US) | 1998-02-24 | — | — | US | disclosed |
| EP-0485157-A2 | Esters and amides of substituted pyrrole acetic acids | FGN, INC. (US) | 1992-05-13 | — | — | EP | disclosed |
| US-3952012-A | MULTISTAGE | MCNEIL LABORATORIES, INCORPORATED (US) | 1976-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010051651-A1 | 1,3,6,-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia | MALT1, VHL, CDKN1A | HTT 2603/4885SRD5A2 223/4885HRH3 1674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.